The commercial courts of the first and appeal instances found in favor of Novartis and abandoned any use of Nativa’s drug before the patent expiry. In December 2016, Novartis sued Nativa for an alleged threat of the patent infringement, which is deemed illegal under the Russian legislation (Civil Code, art. In a few years, Nativa obtained the MA for its generic drug Nilotinib-Nativ (same INN) and has put efforts for the launch of the generic drug (in particular, registered the price before the MoH and applied for the reimbursement), regardless of Novartis’ effective patent for Nilotinib. Under the auspices of the case, in 2008 Novartis obtained the MA for its blockbuster drug Tasigna (INN Nilotinib).
#Nativa 2016 colombia registration#
The IP Court’s position in this case may result in an extra defense granted for patent holders against unfair practice of registration of generics drugs until patent expiry. On 24 April 2018 the Intellectual Property Court published its Decision in case A41 85807/2016 between Swiss-based Novartis AG and local generic Nativa LLC. Khiron Wellbeing is the company’s consumer-product segment, which handles Kuida, a consumer brand of cannabis-based products for “beauty, lifestyle, fitness, nutrition and healthy living.”įeatured image courtesy of Khiron Life Sciences.By Boris Malakhov of Lidings Law Firm on NovemPosted in Case Studies, Europe, Patents Khiron Health Services manages two clinics in Colombia that work with cannabis as an alternative medicine, and also offer an array of traditional medical services including neurological, psychiatric, respiratory, urological, sleep and orthopedic attention.
#Nativa 2016 colombia iso#
The company has an yearly cultivation capacity of 8,000 kilograms of dried flower and owns a 14,000 square-feet (0.13 hectares) extraction facility that is GMP and ISO compliant. The segment was also selected to provide cannabis products to Project Twenty21, a European initiative to facilitate access of medical cannabis. Sales of Khiron’s medical high-THC cannabis commenced in Colombia in Q1 2020. Khiron Med commercializes THC and CBD products to pharmacies in Colombia and at Khiron’s own medical clinics. The startup was founded in 2017 and carries three business segments: Med, Health Services and Wellbeing. Khiron Life Sciences KHRNF is a vertically-integrated cannabis producer with core operations in Colombia. Pura Earth is Avicanna’s CBD derma-cosmetic consumer brand, which launched for the Colombian market in November 2019, and plans to expand globally. The Colombian facilities produce THC, CBD, CBG and other rare cannabinoids that are utilized for the company’s finished products and also offered to the global marketplace under the Aureus Santa Marta brand.Īvicanna also owns Rho Phyto, a medical cannabinoid brand currently in commercialization in Canada through an exclusive partnership with Shoppers Drug Mart. The two make up 410,000 square feet (3.8 hectares) of cultivation capacity with production capacity of over 30,000 kg of biomass per year. The company also cultivates and processes cannabinoids through its two majority-owned subsidiaries, Sativa Nativa and Santa Marta Golden Hemp, both located in Santa Marta, Colombia. The company was co-founded in 2016 by Setu Purohit and Aras Azadian, who serve as president and CEO, respectively.Īvicanna is headquartered at the Johnson & Johnson JLABS Innovation Centre in Toronto, where it handles R&D operations and exercises an exclusive research agreement with the Leslie Dan Faculty of Pharmacy at the University of Toronto. Photo courtesy of Avicanna.Īvicanna AVCN AVCNF is a bio-pharmaceutical company focused on the development and commercialization of cannabinoids exclusively for the medical cannabis, health and wellness markets. In 2019, the company also received authorization to cultivate medical cannabis in Portugal, and has started operations in a 90-hectare Portuguese farm.
Its extraction facility is currently capable of extracting 2,400 kilograms of dried flowers per month. Iqanna is Clever Leave’s pharmaceutical branch, focused on the research, cultivation, extraction, processing, and distribution of medicinal cannabis.Īdditionally, Clever Leaves manages three wellness and beauty consumer brands and has a portfolio of other cannabis companies in its investment platform.
It’s the only private company in the group of four.Ĭlever Leaves commercializes crude cannabis oils, distillates and isolates, as well as finished products through its B2B wholesaler platform called Clever Leaves 360. Clever Leaves is a producer of medical cannabis and hemp extracts that currently cultivates over 1.8 million square feet (16.7 hectares) of greenhouses in Colombia.įounded in 2016 by Andres Fajardo, Julian Wilches and Gustavo Escobar, the company merged in 2019 with Northern Swan, its main investor, making Kyle Detwiler the CEO.
0 kommentar(er)
